Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$3.5 - $6.9 $2,208 - $4,353
-631 Reduced 0.52%
121,107 $49,000
Q3 2021

Nov 12, 2021

BUY
$8.2 - $12.4 $763,657 - $1.15 Million
93,129 Added 325.52%
121,738 $113,000
Q1 2021

May 13, 2021

SELL
$15.2 - $25.0 $47,120 - $77,500
-3,100 Reduced 9.78%
28,609 $460,000
Q4 2020

Feb 09, 2021

BUY
$11.2 - $27.7 $355,140 - $878,339
31,709 New
31,709 $659,000

About Cellectar Biosciences, Inc.


  • Ticker CLRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 6,114,290
  • Market Cap $1.47M
  • Description
  • Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...
More about CLRB
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.